Inactive Instrument

Other languages Bio-Path Holdings Inc OTC Bulletin Board

Equities

BPTH

US09057N1028

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Jun. 14	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	CI
Jun. 05	Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	Jun. 14
Sector Update: Health Care Stocks Gain Late Afternoon	Jun. 03
Top Midday Gainers	Jun. 03
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	Jun. 03
Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session	Jun. 03
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At American Society of Clinical Oncology Annual Meeting	Jun. 03
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	Apr. 18
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	Apr. 15
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 10
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia	Dec. 14
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Bio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia	23-08-01
Top Premarket Decliners	23-06-26
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Bio-Path Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
Bio-Path Holdings, Inc. Provides Clinical and Operational Update	23-03-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bio-Path Holdings Inc OTC Bulletin Board

Equities

BPTH

US09057N1028

Other languages

Filters